PubMed Health⌕ Search

Biomedical subjects

S Murawiec

Publications and source records attributed to S Murawiec.

6 recordsLinked to original sources
PubMedDate not supplied

[Subjective aspects of psychopharmacology in schizophrenia].

The authors discuss the subjective and psychodynamic aspects of pharmacotherapy in schizophrenia which are important for compliance. A large number of different factors connected with psychopharmacotherapy are of particular importance when we consider their impact on compliance. Those factors are psychopathology of patient's disease, insight, and his her intrapsychic structure as well as the great number of factors which are based on social and cultural environment of the patient. One of the most important factors is associated with the patient's family and the question how the family estimate the changes in the patient's health under the influence of medication. Other important factors include those which are rooted in the therapeutic environment of mental health service institutions and particularly in the therapeutic relationship between the patient and the treating psychiatrist. Those factors, including transference and counter-transference, may cause specific impact or even distortions ona farmacotherapeutic action of the antipsychotic drugs. The attempts to classify this compound area as well as some remarks concerning meaning of psychodynamic aspects of farmacotherapy for different groups of mental health professionals are presented in the article. The psychodynamic and subjective factors of psychopharmacotherapy are seen here as a part of a more complex field of compliance but also as those which determine a successful therapeutic outcome in the care of schizophrenic patients.

Antipsychotic Agents↗
PubMedDate not supplied

[Psychological conditions of patient's decision to break off the treatment with atypical neuroleptic: a case study].

Patient's compliance is an important factor in treatment of schizophrenia. As a part of a wide field of compliance problems, subjective experiences of neuroleptic therapy are important for adherence to treatment. Not only pharmacological action of the given drug but also the patient's subjective and psychological experiences of this action and his/her interpretations of what he/she feels are crucial for the successful treatment of schizophrenia. The change in patient's mental state is followed by changes in patient's intrapsychic attitudes, thoughts and emotions, in his/her relationship with the important persons in environment and with the global social milieu as well. In this paper the case of a psychotic patient was described. The patient responded well to low doses of risperidone but then refused to continue the treatment. Her refusal can be understood in terms of her inability to face developmental tasks (separation process) and interpreted in psychodynamic manner. It is also clear that it has transferential meaning. In conclusions the '"awakening" problem' is described. In some cases after treatment with atypical neuroleptics good clinical improvement can be seen. Sometimes it is coined as "awakening". Many "awakened" patients experience novel set of challenges after reduction in psychotic symptoms. If it is too difficult for them to try to solve these problems, like it was in the case described above, they can drop out the treatment.

Adult↗
PubMedDate not supplied

[Neuroleptics, atypical antipsychotics and "awakening"].

Clinical response to the treatment of schizophrenic patients with atypical antipsychotics is sometimes labeled as "awakening". However, there is no general agreement what this term specifically means. The wide range of definitions starts from withdrawal of side effects of classical neuroleptics and goes through psychological phenomena to the definition that postulates arresting of the psychotic process. The paper presents a review of different points of view on "awakening" phenomena as well as problems that are connected with it. Some own experiences and attempts at generalization are presented. They deal with new problems and challenges connected with treatment of patients with acute and chronic schizophrenia with atypical antipsychotics.

Antipsychotic Agents↗
PubMedDate not supplied

[Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs].

Subjective and objective evaluation of pharmacological treatment was made in 105 schizophrenic in-patients. PANSS and Calgary scale as well as Van Putten scale were used. Fifty-four percent of subjects received classic neuroleptics and 46%--new atypical drugs for an average period of 8 weeks. The severity of schizophrenic symptoms during treatment as well as subjective evaluation of first effects of the drug did not differ among subjects treated with classic or atypical drugs. Depressive symptoms decreased significantly during treatment with atypicals but not with classic drugs. Also a significant decrease of depression was found under olanzapine treatment. The severity of neuroleptic-induced side-effects did not differ in both groups. Neurological side effects were more prominent in subjects after 4 weeks of therapy with risperidone, in comparison to patients receiving olanzapine. Forty-seven per-cent of patients showed a dysphoric reaction to the first dose of medication. After treatment with atypical drugs, better subjective evaluation of pharmacotherapy correlated with less severe general and depressive schizophrenia symptoms. Patients' better evaluation of olanzapine treatment correlated with less severe schizophrenic general symptomatology. The subjective evaluation of treatment was better in patients with less severe neurological side-effects of atypical drugs (including olanzapine but not risperidone) and less severe autonomic side-effects of classic drugs. The evaluation of pharmacotherapy made by patients' family members did not correlate with subjects' opinions after distribution of the first dose of the drugs, but correlated significantly with patients' opinion after 8-weeks of treatment. The treatment received by the patients was judged better by the family members if less severe neurological side-effects were present.

Adult↗